imatinib mesylate has been researched along with Lymphoma, Follicular in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashizawa, M; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Sato, K; Shirato, Y; Sugimoto, M; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Kobayashi, Y | 1 |
| Chand, M; Keung, YK; Thakuri, M | 1 |
1 review(s) available for imatinib mesylate and Lymphoma, Follicular
| Article | Year |
|---|---|
Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD20; Benzamides; Biomarkers; Drugs, Investigational; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
2 other study(ies) available for imatinib mesylate and Lymphoma, Follicular
| Article | Year |
|---|---|
Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Topics: Aniline Compounds; Dasatinib; Drug Substitution; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Time Factors; Treatment Outcome | 2018 |
Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Neoplasms, Second Primary; Piperazines; Pyrimidines | 2004 |